Navigation Links
Intercept Pharmaceuticals Raises $25 Million Series B Financing
Date:1/25/2010

NEW YORK, Jan. 25 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for chronic fibrotic and metabolic diseases, today announced the completion of a $25 million Preferred Series B financing by its majority shareholder Genextra S.p.A.

Dr. Mark Pruzanski, founder, President and CEO commented, "This financing is recognition of the success we have had advancing our lead compounds INT-747 and INT-777. Genextra's strong backing will enable us to advance our clinical programs while continuing to build our pipeline of novel small molecules targeting FXR, TGR5 and other bile acid receptors."

In conjunction with the financing, Dr. Lorenzo Tallarigo, CEO of Genextra and Intercept director, is assuming the role of Chairman. Dr. Tallarigo stated, "This financing adds substantially to Genextra's investment in Intercept. With two positive Phase II studies last year, the company has made great progress in validating the therapeutic utility of INT-747 and the novel class of compounds it belongs to more broadly."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

About INT-747 (first-in-cla
'/>"/>

SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
2. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
3. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
4. Amylin Pharmaceuticals to Webcast Year-End Financial Results
5. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
6. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
7. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
8. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
9. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... DIEGO and CARDIFF-BY-THE-SEA, Calif. ... Inc. (NASDAQ: SRNE ;  Sorrento), an ... associated pain, and Conkwest, Inc., a privately-held immuno-oncology ... Natural Killer (NK) cell-line based therapy, announced today ... agreement to jointly develop next generation CAR-TNK™ (pronounced ...
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... media event held today at the,Dello Russo Laser Vision ... and Jeffrey Dello Russo introduced the most advanced,eye laser ... Since Dr. Joseph Dello Russo introduced laser eye ... associated with the "firsts" in lasik evolution,leading the implementation ...
... Nov. 21 Alliance Pharmaceutical,Corp. (OTC Bulletin ... week in China with its partner Beijing ... its clinical development,plan for Oxygent(TM) (perfluorochemical [PFC] ... clinical development of Oxygent in China. The,clinical ...
Cached Medicine Technology:Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan 2
(Date:12/19/2014)... (PRWEB) December 19, 2014 Surviving Mesothelioma says ... EPA information indicates that these pipes can leach asbestos into ... to the full story on the Surviving Mesothelioma website. ... erosion of natural asbestos deposits, decaying water mains made of ... water. , To protect consumers from mesothelioma , ...
(Date:12/19/2014)... 2014 B. E. Smith, the only ... has been retained to lead a national chief ... in Estes Park, Colo. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... not-for-profit critical access hospital and level IV trauma center, ...
(Date:12/19/2014)... Novellus Healthcare Communications, LLC announces ... Clinics™, an independent journal that provides practical information ... for patients inside the pharmacy and retail clinics. ... optimal access to quality care, Inside Patient Care: ... team treating and coordinating patient care in pharmacies ...
(Date:12/19/2014)... 2014 If you have ever been ... you probably wished you had an arsenal of treatments ... fibrosis, and other breathing disorders. Currently, the only proven ... triggers, but other common treatments do exist. At ... San Antonio, TX, 34 asthma educators responded to a ...
(Date:12/19/2014)... 2014 After a 13-year absence from ... returning to the stage to entertain his many worldwide ... performances, and the successful tour has been steadily expanding ... , Visit Ticketability.com for a large inventory ... at fair prices. , Music fans have had a ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2
... Annual Meeting of SNM, the world's largest society ... German researchers stated that early metabolic imaging with ... to chemotherapy for esophageal cancer. ,"This ... from early metabolic response assessment to clinical decision ...
... Phase II studies of pazopanib in advanced or ... and soft tissue sarcoma (STS). These trials were ... American Society of Clinical Oncology (ASCO) in Chicago. ... support further investigations. ,Pazopanib is an ...
... as the earth endures, seedtime and harvest, cold and heat, summer ... ,- (Genesis 8:22, The Bible ). ,Our ... say, we, the people, of this planet earth, are to be ... our very existence. , ,Awareness ...
... already revealed that stress boosts the production of a ... study on mice has now shown that blocking a ... study, reported online in the Proceedings of the National ... of Medicine in St. Louis, is among the first ...
... tumor cell activity in women differs according to age, leading to ... ,Breast cancer tends to be more aggressive and less responsive ... and the study may lead to targeted therapies that can help ... by a team of researchers led by Carey Anders at the ...
... Duke University Medical Center has found that Flaxseed, an edible ... compounds known as lignans, is effective in halting prostate ... seed, which is similar to a sesame seed, may be ... to divide irregularly and become cancerous. ,The study, ...
Cached Medicine News:Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 2Health News:Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 3Health News:Pazopanib Shows Positive in Advanced Renal Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma 4Health News:World Environment Day (International Polar Year) 2Health News:World Environment Day (International Polar Year) 3Health News:World Environment Day (International Polar Year) 4Health News:Stress Protein Inactivation Cuts Alzheimer's Peptide in Mice 2Health News:Flaxseed Helps in Reducing the Risk of Prostate Tumor Spread 2
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records....
... is a subscription-based service, which enables you ... record software without purchasing or maintaining the ... a computer server. All you need is ... cable, which will allow you to connect ...
... is dedicated to serving the needs ... ultimate tool to,run a better orthopaedic ... records software.,AcerMed's Orthopaedic-Edition EMR software has ... surgeons across the country resulting in ...
AllMeds was the first specialty-specific Electronic Medical Record for Neurosurgery. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Neu...
Medicine Products: